To date, approximately 119 pathogenic variants in the ALAS2 have been reported in patients with XLSA, and the mutations are mainly attributed to the hypermutability of CpG dinucleotides, which also contributes to the relative frequency of de novo mutations in this disease (2, 14). This evidence concerns the gene ALAS2 and X-linked sideroblastic anemia 1.